Neobiosis

Neobiosis is a private, pre-revenue biotechnology company founded in 2015, headquartered in Tampa, Florida, with key operations in Gainesville. The company is developing a platform based on perinatal tissues (cells, EVs, matrix) for regenerative applications, inspired by the principles of heterochronic parabiosis. Its dual business model combines internal therapeutic R&D with CDMO services for external partners, positioning it within the high-growth regenerative medicine and cell therapy manufacturing sectors. Leadership consists of experienced physician-scientists, and the company operates from FDA-registered and state-inspected facilities.

Proprietary platform for isolating cells, extracellular vesicles (EVs), and matrix from perinatal tissues (amniotic fluid, placenta, umbilical cord) for regenerative applications, inspired by heterochronic parabiosis principles.

Neobiosis competes with other perinatal tissue processing companies and broader regenerative medicine CDMOs. Its differentiation lies in its specialized platform technology, physician-scientist leadership, and operational base within a top biotech incubator.